Presentazione Mario Venditti - Istituto Superiore di Sanità

More documents

Recommendations

Info

Combination antibiotic therapy for KPC+ KP • Forty KPC-KP bacteremias in 2 me<strong>di</strong>cal centers • Me<strong>di</strong>an APACHE II score was 20 (range, 3-44) • Higher mortality (70 vs 37%) when pneumonia source. • Regimens with poly, tige, penems, alone or in combo. • Lower death rate with combo vs. mono (15 vs. 59%; P
100 25 50 75 0 KPC bacteremia Tumbarello M, Viale PL, Bassetti M unpublished data Kaplan-Meier survival estimates of 125 patients who received adequate therapy 0 10 20 30 Days Combination therapy Monotherapy
Page 1 and 2: Klebsiella pneumoniae resistente ai
Page 3 and 4: Caso clinico 5 • Maschio 73 aa, o
Page 5 and 6: Confronto di caratteristiche clinic
Page 7 and 8: Klebsiella KPC 3 + Ompk35/Ompk36v -
Page 9: 50 45 40 35 30 25 20 15 10 5 0 11 T
Page 12 and 13: Significato clinico di VIM1+ & resi
Page 14 and 15: K. pneumoniae Carbapenem resistente
Page 16 and 17: CMS Colistin Colistin (3 milion U C
Page 18 and 19: Concentrazioni sieriche di colistin
Page 22 and 23: Aumento delle MIC per colistina in
Page 24 and 25: Livelli sierici e liquorali in cors
Page 26 and 27: Relazione tra ABS al picco (P) ed a
Page 28 and 29: Significato clinico di VIM1+ & resi
Page 30 and 31: Trattamento delle infezioni da K pn
Page 34 and 35: Multivariate analysis of factors as
Page 36 and 37: Antibiogramma con Vitek 2
Page 38: Area della resistenza relativa di I
Page 44 and 45: Antibiotics in critically ill patie
Page 46: Bisogna ottimizzare diagnosi microb

Presentazione Mario Venditti - Istituto Superiore di Sanità

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?